Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus

被引：25
|
作者：
Chatzidionysiou, Katerina [1 ]
Samoli, Evangelia [2 ]
Sfikakis, Petros P. [1 ]
Tektonidou, Maria G. [1 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Dept Propaedeut & Internal Med 1, Joint Rheumatol Program, Laiko Hosp,Med Sch, Athens, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷 / 02期
关键词：
D O I：
10.1136/annrheumdis-2019-216367
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：304 / +
页数：4
相关论文
共 50 条
  • [1] Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al
    Bettiol, Alessandra
    Pregnolato, Francesca
    Sciascia, Savino
    Emmi, Giacomo
    Prisco, Domenico
    Meroni, Pier Luigi
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08)
  • [2] Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al' by Bettiol et al
    Chatzidionysiou, Katerina
    Samoli, Evangelia
    Sfikakis, Petros P.
    Tektonidou, Maria G.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (08)
  • [3] Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials
    Parodis, Ioannis
    Emamikia, Sharzad
    Gomez, Alvaro
    Gentline, Cidem
    Arkema, Elizabeth, V
    Chatzidionysiou, Katerina
    van Vollenhoven, Ronald F.
    LANCET RHEUMATOLOGY, 2019, 1 (03): : E163 - E173
  • [4] Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
    Manzi, Susan
    Sanchez-Guerrero, Jorge
    Yokogawa, Naoto
    Wenzel, Joerg
    Ocran-Appiah, Josephine C.
    Khamashta, Munther
    Harris, Julia H. N.
    Rubin, Bernie
    Fox, Norma Lynn
    Levy, Roger A.
    Werth, Victoria
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1933 - 1935
  • [5] Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab
    Jagerback, Sandra
    Gomez, Alvaro
    Parodis, Ioannis
    RHEUMATOLOGY, 2024,
  • [6] PREDICTORS OF RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS: A POST-HOC ANALYSIS OF FOUR PHASE III CLINICAL TRIALS OF BELIMUMAB
    Jagerback, S.
    Gomez, A.
    Parodis, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 34 - 34
  • [7] Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
    Parodis, Ioannis
    Lindblom, Julius
    Levy, Roger A.
    Zen, Margherita
    Cetrez, Nursen
    Gomez, Alvaro
    Oon, Shereen
    Henning, Christine
    Khamashta, Munther
    Quasny, Holly A.
    Chauhan, Deven
    Askanase, Anca
    van Vollenhoven, Ronald
    Nikpour, Mandana
    LANCET RHEUMATOLOGY, 2024, 6 (11): : e751 - e761
  • [8] Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
    Navarra, Sandra V.
    Guzman, Renato M.
    Gallacher, Alberto E.
    Hall, Stephen
    Levy, Roger A.
    Jimenez, Renato E.
    Li, Edmund K-M
    Thomas, Mathew
    Kim, Ho-Youn
    Leon, Manuel G.
    Tanasescu, Coman
    Nasonov, Eugeny
    Lan, Joung-Liang
    Pineda, Lilia
    Zhong, Z. John
    Freimuth, William
    Petri, Michelle A.
    LANCET, 2011, 377 (9767): : 721 - 731
  • [9] Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial
    M Diana van Die
    Kerry M Bone
    Henry G Burger
    Helena J Teede
    BMC Medical Research Methodology, 9
  • [10] Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
    Brunner, Hermine, I
    Abud-Mendoza, Carlos
    Viola, Diego O.
    Calvo Penades, Inmaculada
    Levy, Deborah
    Anton, Jordi
    Calderon, Julia E.
    Chasnyk, Vyacheslav G.
    Ferrandiz, Manuel A.
    Keltsev, Vladimir
    Paz Gastanaga, Maria E.
    Shishov, Michael
    Boteanu, Alina Lucica
    Henrickson, Michael
    Bass, Damon
    Clark, Kenneth
    Hammer, Anne
    Ji, Beulah N.
    Nino, Antonio
    Roth, David A.
    Struemper, Herbert
    Wang, Mei-Lun
    Martini, Alberto
    Lovell, Daniel
    Ruperto, Nicolino
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) : 1340 - 1348
12345